Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New study points the way to therapy for rare cancer that targets the young

22.11.2017

After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar hepatocellular carcinoma (FL-HCC), which mainly strikes adolescents and young adults.

Sanford Simon, who conducted the research as head of The Rockefeller University's Laboratory of Cellular Biophysics, describes the culprit as a "chimeric gene," a mutation created when two genes fuse together. These genes normally sit far apart from each other, separated by some 400,000 base pairs, the building blocks of DNA that combine to form genes.


This is a cross-section of a normal human liver (left) and one transformed by fibrolamellar carcinoma.

Credit: Laboratory of Cellular Biophysics at The Rockefeller University

Usage Restrictions: Image may be used only to illustrate the research described in the accompanying release.

The chimeric gene, which Simon's lab first characterized three years ago, has been found in each of the hundreds of FL-HCC patients tested for the mutation.

A disease mechanism revealed

Having confirmed the chimeric gene as a hallmark of the disease, Simon set out to explore if and how it may cause these malignant tumors. He worked with Scott Lowe, a cancer geneticist at the Memorial Sloan Kettering Cancer Center, to develop a mouse model of FL-HCC.

In work published this week in the Proceedings of the National Academy of Sciences, the scientists used CRISPR gene editing, a highly precise tool for manipulating DNA, to generate mice that carry the 400,000 base-pair deletion and produce the chimeric gene.

Edward Kastenhuber, a graduate student in Lowe's lab, found that these mice develop liver tumors that mimic the biology of the tumors found in humans with FL-HCC, suggesting that the deletion is in itself sufficient to cause the cancer--other alterations are not necessary for tumors to grow.

However, this experiment left open the question of precisely how the deletion spurs cancer: by eliminating genes that normally would suppress the growth of tumors, or by introducing the chimeric gene. Another experiment, in which mice with the fused gene but no deletion in the genome developed tumors, proved that it's the mutation, not the missing DNA as such, that causes the disease.

With the chimeric gene firmly established as the driver of the disease, and its cellular mechanisms defined, Simon and his team--including Gadi Lalazar, of Rockefeller's Clinical Scholars Program, and graduate student David Requena--are now working to identify potential targets for drugs to treat the disease.

New concepts for therapy

Among these drug targets is a protein produced from the fused gene that belongs to a family of enzymes called kinases. These enzymes are often mutated in cancers. "In fact," Simon explains, "some of the most successful cancer therapies available, including Gleevec, act by targeting specific kinases."

The researchers showed that disruption of the fused gene's kinase activity impaired the formation of tumors in mice--a finding that has strengthened their confidence that agents aimed at targeting this activity or its consequences might be effective against FL-HCC.

The team is also studying the effects of targeting a number of cellular signaling systems that have previously been implicated in other cancers, and that speed tumor growth when they become overactive in FL-HCC patients. And they will be using their new mouse model as a system to test the effectiveness of new therapies prior to initiating clinical trials in patients.

Simon first became interested in FL-HCC nine years ago, when his 12-year-old daughter Elana was diagnosed with the disease. (Now 21, Elana is a senior at Harvard, and a lead author on earlier reports characterizing the genomics of the disease.) He continues to embrace the challenge the cancer presents and attributes the latest breakthroughs to an "incredible perfect storm" of advances in all of the sciences, thanks to decades of public investment in basic research.

"Here's a cancer where, five years ago, we didn't know if it was one disease or many diseases lumped together," Simon adds. "We didn't know if it was inherited or if it was due to a sporadic mutation. And now we know exactly what the driver is and how it works, and we can start designing therapeutics."

Media Contact

Katherine Fenz
kfenz@rockefeller.edu
212-327-7913

 @rockefelleruniv

http://www.rockefeller.edu 

Katherine Fenz | EurekAlert!

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First diode for magnetic fields

Innsbruck quantum physicists have constructed a diode for magnetic fields and then tested it in the laboratory. The device, developed by the research groups led by the theorist Oriol Romero-Isart and the experimental physicist Gerhard Kirchmair, could open up a number of new applications.

Electric diodes are essential electronic components that conduct electricity in one direction but prevent conduction in the opposite one. They are found at the...

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

Removing toxic mercury from contaminated water

21.11.2018 | Life Sciences

New China and US studies back use of pulse oximeters for assessing blood pressure

21.11.2018 | Medical Engineering

Exoplanet stepping stones

21.11.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>